Posters

Intravitreal dexamethasone implant for the treatment of idiopathic macular telangiectasia

Poster Details

First Author: V.Vinals Bosch SPAIN

Co Author(s):    K. Mousavi   J. Casado Martin   S. Moreno Ferrer   E. Pedemonte Sarrias                    

Abstract Details



Purpose:

To evaluate the efficacy of intravitreal dexamethasone implant (IDI) for the treatment of idiopathic macular telangiectasia (IMT).

Setting:

Hospital Universitari Mutua Terrassa (Terrassa, Barcelona, Spain).

Methods:

Retrospective case series report of six eyes (six patients) with macular edema secondary to IMT treated with IDI. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded. All patients underwent complete ophthalmic examination, spectral domain optical coherence tomography and fluorescein angiography.

Results:

The median CMT at baseline was 345 µm (306-514 µm) and diminished to 280 µm (257-313 µm) after the first injection (42 days after in average). The median BCVA at baseline was LogMAR 0.40 (0.2-0.8) and after the first injection was LogMAR 0.40 (0.2-0.7). The median follow-up period and the median number of injections received were 8 months and 1.5 injections per patient respectively. The median CMT at the last control was 301 µm (264-442 µm) and the median BCVA was LogMAR 0.40 (0.1-0.8).

Conclusions:

Intravitreal dexamethasone implant might be an effective treatment for macular edema due to idiopathic macular telangiectasia. The BCVA maintains or improves after the first injection of IDI on these patients; even BCVA tends to diminish during the follow-up. IDI has greater impact on controlling CMT than on improving BCVA.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy